Scarica l'app Stockscreener
1.34
2.29%
0.03
Dopo l'orario di chiusura:
1.32
-0.02
-1.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.31
Aprire:
$1.32
Volume 24 ore:
1.34M
Relative Volume:
1.00
Capitalizzazione di mercato:
$49.14M
Reddito:
$832.00K
Utile/perdita netta:
$-135.12M
Rapporto P/E:
-0.22
EPS:
-6.09
Flusso di cassa netto:
$-124.69M
1 W Prestazione:
-7.59%
1M Prestazione:
-33.00%
6M Prestazione:
-29.84%
1 anno Prestazione:
-87.96%
Intervallo 1D:
$1.305
$1.35
Intervallo di 1 settimana:
$1.30
$1.47
Portata 52W:
$1.30
$12.33
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Nome
Inovio Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 410-3134
Indirizzo
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Confronta INO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.34 | 68.29M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.40 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.77 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-01-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Downgrade | Maxim Group | Buy → Hold |
| 2022-11-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Ripresa | Jefferies | Hold |
| 2021-09-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Iniziato | Jefferies | Hold |
| 2021-03-23 | Iniziato | BofA Securities | Neutral |
| 2021-02-12 | Iniziato | Oppenheimer | Outperform |
| 2020-11-17 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Aggiornamento | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-01 | Downgrade | Maxim Group | Buy → Hold |
| 2020-07-01 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Downgrade | Stifel | Buy → Hold |
| 2020-05-21 | Iniziato | The Benchmark Company | Buy |
| 2020-04-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Iniziato | ROTH Capital | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
| 2017-10-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Iniziato | Citigroup | Buy |
| 2017-06-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Reiterato | Maxim Group | Buy |
| 2017-03-16 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-03-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mostra tutto
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
INOVIO to Present DNA Medicine Innovations for Rare Diseases at Orphan Drug Summit - MyChesCo
Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug - MSN
INOVIO Announces Pricing of $25 Million Public Offering - Kilgore News Herald
Inovio Pharmaceuticals (INO) Set for Growth With Potential FDA N - GuruFocus
Inovio stock on Piper Sandler's bullish view (INO:NASDAQ) - Seeking Alpha
This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Inovio Pharmaceuticals at Overweight With $5 Price Target - MarketScreener
Inovio (INO) Gains Favorable Analyst Rating with $5 Price Target - GuruFocus
Inovio Pharmaceuticals Announces Public Offering Agreement - The Globe and Mail
INOVIO Pharmaceuticals: Pioneering Rare Disease Therapies with DNA-Encoded Antibodies - AInvest
INOVIO to Present at Upcoming Scientific Conference - StreetInsider
INOVIO to Present at Upcoming Scientific Conference | INO Stock News - GuruFocus
INOVIO's Revolutionary DNA Medicine Technology Takes Center Stage at Major Rare Disease Conference - Stock Titan
INOVIO Announces Public Offering of Common Stock and Warrants - MSN
Inovio Pharmaceuticals announces proposed public offering of common stock and warrants - MSN
Inovio Pharmaceuticals Plunges 29.44% on $25M Offering - AInvest
Inovio Stock’s Unexpected Dive - StocksToTrade
INOVIO Announces Pricing of $25 Million Public Offering | INO Stock News - GuruFocus
Inovio prices $25 million public offering of common stock and warrants - Investing.com
Inovio prices $25 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals stock plunges after announcing public offering By Investing.com - Investing.com India
INOVIO announces proposed public offering of common stock By Investing.com - Investing.com South Africa
INOVIO Pharma Announces Proposed Public Offering - Nasdaq
Inovio Pharmaceuticals (INO) Announces Public Offering Plan - GuruFocus
Inovio Pharma dives on equity offering plans - TradingView
Inovio Pharmaceuticals stock plunges after announcing public offering - Investing.com
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from Russell Small Cap Completeness Index - MarketScreener
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) dropped from Russell 3000 Value Index - MarketScreener
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides
Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World
Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio shareholders approve board nominees and proposals - Investing.com Australia
Inovio Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight - The Globe and Mail
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines - MyChesCo
Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst - Defense World
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Inovio Pharmaceuticals (INO) Sees Price Target Adjustment by Opp - GuruFocus
Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN
Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus
Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus
Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks
Inovio Pharmaceuticals Inc Azioni (INO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.38%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):